0

524572

PHARMAID

img img img img
No Data Available

Pharmaids Pharmaceuticals Share Price Update

As of the latest trading session, PHARMAIDS PHARMACEUTICALS LTD. is trading at ₹30.88, up by ₹0.62 or 2.04% from its previous close. The stock has moved between ₹29.51 and ₹31.94 today. Over the past year, the stock has delivered a return of -54.33%. In the last month, it has returned -5.68%.

Investment Returns

Over 1 Month -5.68% Over 3 Months -32.21% Over 6 Months -39.38% Over 1 Year -54.33%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

Pharmaids Pharmaceuticals fundamentals


  • Market cap (Cr) [-]
  • P/E Ratio (TTM) [-]
  • Beta [-]
  • Book Value / share [-]
  • Return on equity [-]%
  • EPS (TTM) [-]
  • Dividend yield [-]%
  • Net profit/quarter (Cr) [-]
info icon alternate text
  • Market cap (Cr) 108.90
  • P/E Ratio (TTM) -8.77
  • Beta 0.45
  • Book Value / share 16.38
  • Return on equity 0.00%
  • EPS (TTM) 0.00
  • Dividend yield [-]%
  • Net profit/quarter (Cr) -3.11
info icon alternate text

Pharmaids Pharmaceuticals Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition
info-icon
Revenue
Net income
Particulars DEC 2025 (Values in Cr)
Revenue 0.83
Operating Expense 5.13
Net Profit -3.11
Net Profit Margin (%) -374.69
Earnings Per Share (EPS) -0.88
EBITDA -3.62
Effective Tax Rate (%) 26.65
Particulars SEP 2025 (Values in Cr)
Revenue 5.97
Operating Expense 11.62
Net Profit -1.65
Net Profit Margin (%) -27.63
Earnings Per Share (EPS) -0.47
EBITDA -1.25
Effective Tax Rate (%) 29.18
Particulars JUN 2025 (Values in Cr)
Revenue 1.12
Operating Expense 7.15
Net Profit -4.36
Net Profit Margin (%) -389.28
Earnings Per Share (EPS) -1.24
EBITDA -4.53
Effective Tax Rate (%) 23.37
Particulars MAR 2025 (Values in Cr)
Revenue 0.13
Operating Expense 4.92
Net Profit -3.06
Net Profit Margin (%) -2353.84
Earnings Per Share (EPS) -0.86
EBITDA -1.68
Effective Tax Rate (%) 19.04
Particulars DEC 2024 (Values in Cr)
Revenue 1.21
Operating Expense 3.06
Net Profit -1.59
Net Profit Margin (%) -131.40
Earnings Per Share (EPS) -0.45
EBITDA -1.73
Effective Tax Rate (%) 13.51
Particulars MAR 2025 (Values in Cr)
Revenue 2.34
Operating Expense 11.95
Net Profit -7.28
Net Profit Margin (%) -311.11
Earnings Per Share (EPS) -2.06
EBITDA -6.23
Effective Tax Rate (%) 15.25
Particulars MAR 2024 (Values in Cr)
Revenue 0.03
Operating Expense 6.91
Net Profit -4.95
Net Profit Margin (%) -16500.00
Earnings Per Share (EPS) -2.18
EBITDA -5.58
Effective Tax Rate (%) 18.71
Particulars MAR 2023 (Values in Cr)
Revenue 0.00
Operating Expense 9.91
Net Profit -7.56
Net Profit Margin (%) 0.00
Earnings Per Share (EPS) -5.86
EBITDA -9.89
Effective Tax Rate (%) 23.71
Particulars MAR 2022 (Values in Cr)
Revenue 3.94
Operating Expense 3.81
Net Profit 0.15
Net Profit Margin (%) 3.80
Earnings Per Share (EPS) 0.14
EBITDA 0.15
Effective Tax Rate (%) 0.00
Particulars MAR 2021 (Values in Cr)
Revenue 8.55
Operating Expense 8.49
Net Profit 0.09
Net Profit Margin (%) 1.05
Earnings Per Share (EPS) 0.09
EBITDA 0.13
Effective Tax Rate (%) 0.00
Particulars MAR 2025 (Values in Cr)
Book Value / Share 16.82
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.36
EBITDA Margin -65.50
Particulars MAR 2024 (Values in Cr)
Book Value / Share 20.43
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.09
EBITDA Margin -81.54
Particulars MAR 2023 (Values in Cr)
Book Value / Share 10.31
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin 0.00
Particulars MAR 2022 (Values in Cr)
Book Value / Share 8.44
ROE % 1.36
ROCE % 1.36
Total Debt to Total Equity 0.00
EBITDA Margin 3.81
Particulars MAR 2025 (Values in Cr)
Book Value / Share 18.09
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.39
EBITDA Margin -266.67
Particulars MAR 2024 (Values in Cr)
Book Value / Share 20.15
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.14
EBITDA Margin -18600.00
Particulars MAR 2023 (Values in Cr)
Book Value / Share 10.46
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin 0.00
Particulars MAR 2022 (Values in Cr)
Book Value / Share 8.44
ROE % 1.36
ROCE % 1.36
Total Debt to Total Equity 0.00
EBITDA Margin 3.81
Particulars MAR 2021 (Values in Cr)
Book Value / Share 8.30
ROE % 0.82
ROCE % 0.82
Total Debt to Total Equity 0.00
EBITDA Margin 1.52
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 2.14
Total Assets 119.85
Total Liabilities 119.85
Total Equity 55.04
Share Outstanding 3
Price to Book Ratio 3.80
Return on Assets (%) -8.99
Return on Capital (%) -11.94
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 4.80
Total Assets 91.34
Total Liabilities 91.34
Total Equity 70.49
Share Outstanding 3
Price to Book Ratio 2.58
Return on Assets (%) -8.72
Return on Capital (%) -10.51
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 12.75
Total Assets 24.58
Total Liabilities 24.58
Total Equity 22.46
Share Outstanding 2
Price to Book Ratio 2.09
Return on Assets (%) -30.72
Return on Capital (%) -33.64
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 0.40
Total Assets 11.11
Total Liabilities 11.11
Total Equity 8.67
Share Outstanding 1
Price to Book Ratio 1.48
Return on Assets (%) 1.30
Return on Capital (%) 1.67
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 0.46
Total Assets 118.68
Total Liabilities 118.68
Total Equity 63.78
Share Outstanding 3
Price to Book Ratio 3.80
Return on Assets (%) -6.13
Return on Capital (%) -7.05
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 2.45
Total Assets 85.00
Total Liabilities 85.00
Total Equity 71.06
Share Outstanding 3
Price to Book Ratio 2.58
Return on Assets (%) -5.82
Return on Capital (%) -5.92
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 12.75
Total Assets 24.54
Total Liabilities 24.54
Total Equity 22.42
Share Outstanding 2
Price to Book Ratio 2.09
Return on Assets (%) -30.77
Return on Capital (%) -33.69
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 0.40
Total Assets 11.11
Total Liabilities 11.11
Total Equity 8.67
Share Outstanding 1
Price to Book Ratio 1.48
Return on Assets (%) 1.30
Return on Capital (%) 1.67
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 0.20
Total Assets 9.11
Total Liabilities 9.11
Total Equity 8.52
Share Outstanding 1
Price to Book Ratio 1.35
Return on Assets (%) 1.02
Return on Capital (%) 1.09
Particulars MAR 2025 (Values in Cr)
Net Income -17.27
Cash from Operations -13.92
Cash from Investing -12.02
Cash from Financing 23.35
Net change in Cash -2.65
Free Cash Flow -1.44
Particulars MAR 2024 (Values in Cr)
Net Income -15.62
Cash from Operations -10.61
Cash from Investing -74.99
Cash from Financing 77.65
Net change in Cash -7.95
Free Cash Flow 12.24
Particulars MAR 2023 (Values in Cr)
Net Income -9.90
Cash from Operations -4.01
Cash from Investing -4.94
Cash from Financing 21.30
Net change in Cash 12.34
Free Cash Flow -2.34
Particulars MAR 2022 (Values in Cr)
Net Income 0.14
Cash from Operations -0.25
Cash from Investing 0.46
Cash from Financing 0.00
Net change in Cash 0.20
Free Cash Flow -0.25
Particulars MAR 2025 (Values in Cr)
Net Income -8.58
Cash from Operations -7.72
Cash from Investing -18.90
Cash from Financing 24.63
Net change in Cash -1.99
Free Cash Flow 1.31
Particulars MAR 2024 (Values in Cr)
Net Income -6.08
Cash from Operations -3.44
Cash from Investing -72.50
Cash from Financing 65.65
Net change in Cash -10.29
Free Cash Flow 12.92
Particulars MAR 2023 (Values in Cr)
Net Income -9.90
Cash from Operations -4.01
Cash from Investing -4.94
Cash from Financing 21.31
Net change in Cash 12.35
Free Cash Flow -2.34
Particulars MAR 2022 (Values in Cr)
Net Income 0.14
Cash from Operations -0.25
Cash from Investing 0.46
Cash from Financing 0.00
Net change in Cash 0.20
Free Cash Flow -0.25
Particulars MAR 2021 (Values in Cr)
Net Income 0.08
Cash from Operations 0.40
Cash from Investing -0.22
Cash from Financing 0.00
Net change in Cash 0.17
Free Cash Flow 0.40
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENT L 35.19 15.23 1.82 269.67 23.12 41.00
BLISS GVS PHARMA LTD 262.60 25.11 2.45 2778.02 105.05 277.80
CIPLA LTD 1294.75 22.00 3.17 104587.66 1165.55 1672.20
FERMENTA BIOTECH LIMITED 319.05 10.61 2.40 939.00 252.15 399.00
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENT L 35.19 33.84 4.90 269.67 23.12 41.00
AMRUTANJAN HEALTH CARE LTD. 575.55 28.78 4.86 1663.95 490.00 789.95
ASTRAZENECA PHARMA IND LT 8501.75 102.17 26.60 21254.38 7630.00 10653.05
BLISS GVS PHARMA LTD 262.60 35.78 2.51 2778.02 105.05 277.80

Pharmaids Pharmaceuticals shareholding pattern

Holding
67.01%
32.98%
Name Shares Category
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)

Pharmaids Pharmaceuticals Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
30.89 2.11 redarrow
red-green-graph indicator
8 Bearish
8 Bullish
  • 5 Days 30.40
  • 26 Days 31.40
  • 10 Days 30.60
  • 50 Days 33.60
  • 12 Days 30.60
  • 100 Days 38.40
  • 20 Days 31.00
  • 200 Days 44.80
30.15 PIVOT
First Support 29.14 First Resistance 30.69 Second Support 28.60 Second Resistance 31.70 Third Support 27.59 Third Resistance 32.24
RSI 39.83 ADX 14.11 MACD -0.78 Williams % R -89.54 Commodity Channel Index (CCI) -89.47
Date 2026-04-24 Week 7651.00 Same Day 3864.00 Month 6638.00
1 Year 0.45 3 Year 0.21
Over 1 Month
-5.68% down
Over 1 Year
-54.33% down
Over 3 Months
-32.21% down
Over 3 Years
4.05% down
Over 6 Months
-39.38% down
Over 5 Years
14.05% down

Pharmaids Pharmaceuticals Corporate Actions

Top Gainers

Top Losers

Pharmaids Pharmaceuticals Share Price

Pharmaids Pharmaceuticals Limited, incorporated in March, 1989 at Hyderabad, Telangana were suppliers of Quality Grade range of speciality chemicals, skin care, hospital care and generic products in the areas of Orthopedic, Neuro and Gastro etc. The technical team used quality proven chemical compounds and standard processing methods maintaining proper hygiene standards.The Company is engaged in the business of contract research and manufacturing services.

Emergent Bio Naturals Limited (EBNL) was amalgamated with the Company in 2019-20 and the Scheme of Amalgamation was effective on September 27, 2019. Pursuant to the Scheme, 69,05,734 Equity Shares were allotted to Shareholders of Emergent Bio Naturals Limited on November 27, 2019.

The Company acquired 25.5% stake as 1st tranche in Anugraha Chemicals, a Partnership Firm, registered under Karnataka Partnership Rules, 1954 on February 1, 2023. Further, it acquired Adita Bio Sys Private Limited, making it wholly owned subsidiary of the Company.

Company acquired additional 28.50% of partnership interest in Anugraha Chemicals totalling to 54% partnership interest and became the subsidiary of the Company in 2024. Company acquired an additional 12.5% partnership interest in Anugraha Chemicals , thereby increasing its total partnership interest to 66.50% in FY25.

Parent organization Indian Private
NSE symbol [-]
Founded 1989
stock
Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Pharmaids Pharmaceuticals Ltd?

Answer Field

Pharmaids Pharmaceuticals Ltd share price is for NSE ₹ 0.00 & for BSE ₹ 30.89 as on Apr 28 2026 03:30 PM.

What is the Market Cap of Pharmaids Pharmaceuticals Ltd Share?

Answer Field

The market cap of Pharmaids Pharmaceuticals Ltd for NSE ₹ 0.00 & for BSE ₹ 108.90 as on Apr 28 2026 03:30 PM.

What is the 52 Week High and Low of Pharmaids Pharmaceuticals Ltd?

Answer Field

The 52 Week High and Low of Pharmaids Pharmaceuticals Ltd for NSE is ₹ 0.00 and ₹ 0.00 and for BSE is ₹ 73.45 and ₹ 27.10.

What is 1 year return for Pharmaids Pharmaceuticals Ltd?

Answer Field

The 1 year returns on the stock has been -53.48%.

What is the P/E Ratio of Pharmaids Pharmaceuticals Ltd Share?

Answer Field

As on Apr 28 2026 03:30 PM the price-to-earnings (PE) ratio for Pharmaids Pharmaceuticals Ltd share is -8.77.

What is the PB ratio of Pharmaids Pharmaceuticals Ltd Share?

Answer Field

As on Apr 28 2026 03:30 PM, the price-to-book (PB) ratio for Pharmaids Pharmaceuticals Ltd share is 16.38.

How to Buy Pharmaids Pharmaceuticals Ltd Share?

Answer Field

You can trade in Pharmaids Pharmaceuticals Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Pharmaids Pharmaceuticals Ltd Share on Bajaj Broking App?

Answer Field

To buy Pharmaids Pharmaceuticals Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Pharmaids Pharmaceuticals Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

close-image

Get Free Demat Account*

+91
close-img

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|